Tesaro (NASDAQ:TSRO) is the latest biotech to see rumors swirl of potential mergers and acquisitions. On the heels of launching Zejula earlier this year, the company could fetch as much as $10 billion in a deal, according to industry watchers. Whether this company gets sold, and at what price, is anyone’s guess, but given the company’s run by Lonnie Moulder, a proven leader with one successful deal already under his belt, it wouldn’t shock me if Tesaro’s on the block.
